Therefore, given the success of low-dose IL-2 therapies in autoimmunity, we set out to test low-dose rIL-15 as treatment in a mouse model of NTS, with a specific focus on TEC health and CD8+ T cell involvement. This evidence concerns the gene IL2 and Autoimmunity.